Comparative Pharmacology
Head-to-head clinical analysis: BARHEMSYS versus PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BARHEMSYS versus PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE.
BARHEMSYS vs PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BARHEMSYS (amisulpride) is a selective dopamine D2/D3 receptor antagonist. It also has weak affinity for serotonin 5-HT2A and 5-HT2B receptors, with no significant activity at other dopamine or serotonin receptor subtypes. Its antiemetic effect is primarily mediated through blockade of D2 receptors in the chemoreceptor trigger zone (CTZ).
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic through blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Phenylephrine is a direct-acting sympathomimetic amine that selectively stimulates α1-adrenergic receptors, causing vasoconstriction and nasal decongestion.
BARHEMSYS (amisulpride) 10 mg intravenously over 2 minutes, once daily for prevention of postoperative nausea and vomiting.
Each 5 mL oral solution contains promethazine hydrochloride 6.25 mg and phenylephrine hydrochloride 5 mg. Adults: 10 mL (2 teaspoonfuls) orally every 4-6 hours as needed; maximum 40 mL (8 teaspoonfuls) per 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily dosing in most patients.
Promethazine: Terminal elimination half-life is approximately 10-14 hours in adults, ranging 5-14 hours; prolonged in hepatic impairment. Phenylephrine: Terminal elimination half-life is approximately 2-3 hours; clinically active for a shorter duration due to rapid metabolism.
Renal excretion accounts for approximately 50% of the dose as unchanged drug; fecal elimination (including biliary) accounts for approximately 30-40%.
Promethazine: Renal excretion of metabolites and unchanged drug accounts for approximately 70-80% of elimination, with about 20-30% excreted in feces via biliary elimination. Phenylephrine: Primarily renal excretion as sulfate conjugates and unchanged drug; about 80% of a dose is excreted in urine within 48 hours, with minor fecal elimination (<10%).
Category C
Category A/B
Antiemetic
Antihistamine / Antiemetic